Clinical Trial Search

Primary: Number of Participants Readmitted Within 30-days Post Hospital Discharge — 13; 145 Participants — p=0.018

Primary: Percentage Change in Depressive Symptoms as Assessed by Hamilton Rating Scale for Depression — 60.83; 61.81 percentage of change in score

Primary: Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23 — 40; 22 Participants

Primary: Karnofsky Performance Status (KPS) Score — 76.67; 76.67 score on a scale — p=1.0

Primary: Operation Time — 146.1; 124.6 seconds

Primary: Number of Participants With Serious Adverse Events and Severe Adverse Events Throughout the Study — 0; 0; 6; 9 Participants

Primary: Effect of TIVA With Ketofol and Ketofol Plus Lidocaine on Extubation Time in Children — 240; 120 second

Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events

Primary: Cardiac Glucose Uptake During Normoxic Rest (µg/Min) — 0.689; 0.540 µg/min — p=0.38

Primary: Time to Complete Wound Healing — 11.8; 11.9; 6.9; 10.9 Days — p=<0.001

Primary: Intensity of Perceived Maternal Pain as Measured by the Visual Analogue Scale (VAS) — 9.5; 18.4 units on a scale

Primary: Safety Outcome: Number of Subjects Experiencing an Adverse Device Effect — 2 Participants

Primary: Time-weighted Sum of the Pain Intensity Difference (SPID) Between VX-150 Versus Placebo as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 24 Hours After the First…

Primary: PRIMARY: Mean Change From Baseline in Reflective Total Nasal Symptom Score (rTNSS) (Equivalence: Per-Protocol Population) — 2.036; 1.904 score on scale

Primary: COVID-19 Hospitalization — 35; 3 Participants